Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasinezumab in GBA‑associated Parkinson's disease to prevent cognitive decline
2024-513496-40-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (GBA-PD) comparing Prasinezumab IV with Placebo IV (2 arms). Primary endpoint: PDCCS. Planned start Oct 2026; status: authorised.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (GBA-PD)
Beyond the preview
Go deeper on 2024-513496-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513496-40-00.